Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Change in Acquisitions & Divestments (2022 - 2023)

Alx Oncology Holdings' Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $58.5 million for Q4 2023.

  • For Q4 2023, Change in Acquisitions & Divestments fell 19.1% year-over-year to $58.5 million; the TTM value through Dec 2023 reached $292.6 million, changed N/A, while the annual FY2025 figure was $134.4 million, 30.77% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2023 was $58.5 million at Alx Oncology Holdings, down from $64.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $115.2 million in Q1 2023 and bottomed at $50.5 million in Q3 2022.